


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A compound of the formula:



wherein

ring A represents a benzene ring, which may have 1 to 3 substituents selected from

- (1) halogen atom,
- (2) nitro,
- (3) cyano,
- (4) hydroxy,
- (5) C₁₋₆ alkyl optionally having 1 to 5 halogen atoms,
- (6) C₆₋₁₄ aryl, which may have 1 to 5 substituents selected from halogen atom, hydroxy, C₁₋₆ alkyl optionally having 1 to 5 halogen atoms, C₁₋₆ alkoxy optionally having 1 to 5 halogen atoms, and C₁₋₆ alkyl-carbonyl optionally having 1 to 5 halogen atoms,
- (7) C₁₋₆ alkoxy optionally having 1 to 5 halogen atoms,
- (8) C₁₋₆ alkylthio optionally having 1 to 5 halogen atoms,

- (9) amino,
- (10) mono- or di-C₁₋₆ alkylamino,
- (11) C₁₋₆ alkyl-carboxamide optionally having 1 to 5 halogen atoms,
- (12) carbamoyl,
- (13) mono- or di-C₁₋₆ alkyl-carbamoyl,
- (14) C₁₋₆ alkyl-carbonyl optionally having 1 to 5 halogen atoms,
- (15) C₁₋₆ alkyl-sulfonyl optionally having 1 to 5 halogen atoms,
- (16) 5- to 7-membered non-aromatic heterocyclic group,
- (17) C₁₋₆ alkoxy-C₁₋₆ alkoxy,
- (18) 5- or 6-membered heterocyclic carbonyl,
- (19) carboxy,
- (20) C₁₋₆ alkoxy-carbonyl,
- (21) 5- or 6- ~~5- to 7-~~ membered aromatic heterocyclic group, which may have 1 to 3 substituents selected from C₁₋₆ alkyl optionally having 1 to 5 halogen atoms,
- (22) C₁₋₆ alkylsulfinyl optionally having 1 to 5 halogen atoms, and
- (23) C₃₋₈ cycloalkyl-C₁₋₆ alkoxy;

B represents a C₁₋₆ alkylene optionally having substituents; Y and Ya are the same or different and each represents a bond, C₁₋₆ alkylene, -CO-, -CO-alkb- or -CO-alkd-O- (alkb and alkd are the same or different and each represents a C₁₋₆ alkylene or a bond);

R¹ and R² are the same or different and each represents a hydrogen atom or C₁₋₆ alkyl;

R³ represents a hydrogen atom;

R⁴ and R⁵ are the same or different and each represents a hydrogen atom or C₁₋₆ alkyl or R⁴ and R⁵, together with the adjacent carbon atom, form a ring optionally having substituents;

R⁶ represents an indolyl group optionally having substituents;

Z represents piperidinyl optionally having substituents or piperazinyl optionally having substituents; and

Za represents a hydrogen atom, a halogen atom or a cyclic group optionally having substituents; or a salt thereof.

2-3. (Canceled)

4. (Original) The compound according to claim 1, wherein one of R⁴ and R⁵ is a hydrogen atom, and the other is a C₁₋₆ alkyl optionally having substituents.

5-6. (Canceled)

7. (Previously Presented) The compound according to claim 1, wherein Z is piperidinyl or piperazinyl, each of which is substituted by a group of the formula: -Yd-Ara wherein Yd is a bond, C₁₋₆ alkylene, -alka-O-alkb-, -alka-S-alkb-, -alka-CO-alkb-, -alka-SO-alkb-, -alka-SO₂-alkb- or -alkc-CO-alkd-NH-alke- (wherein alka, alkb, alk, alkd and alke are the same or different and each represents a C₁₋₆ alkylene or a bond), and Ara represents a monocyclic group optionally having substituents.

8. (Original) The compound according to claim 1, wherein Ya is a bond, and Za is a hydrogen atom.

9. (Original) The compound according to claim 1, wherein B is a C₁₋₆ alkylene.

10. (Canceled)

11. (Original) The compound according to claim 1, wherein R¹ and R² are C₁₋₆ alkyl.

12. (Original) The compound according to claim 1, wherein Y is -CO-.

13. (Original) The compound according to claim 1, which is

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-((methylamino)carbonyl)phenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(2-methylphenyl)-1-piperidinecarboxamide;

N-((1R,2S)-1-(((2-((dimethylamino)carbonyl)-5-((dimethylamino)methyl)phenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(4-fluorophenyl)-1-piperidinecarboxamide;

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-methoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(4-fluoro-2-methylphenyl)-3-oxo-1-piperazinecarboxamide;

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-methoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(2-methylphenyl)-1-piperazinecarboxamide;

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-ethoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(4-fluorophenyl)-1-piperazinecarboxamide; or

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-ethoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-phenyl-1-piperidinecarboxamide.

14. (Previously Presented) A pharmaceutical preparation comprising the compound according to claim 1 or a salt thereof.


15-23.

24. (Currently Amended) A method for treating diabetes ~~type 1 or type 2,~~
~~diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, Doan syndrome or~~

orthostatic hypotension in a mammal, which comprises administering to the mammal an effective amount of the compound according to claim 1 or a salt thereof.

25-26. (Canceled)

27. (Currently Amended) A method for producing a compound of claim 1 or a salt thereof, which comprises reacting a compound of the formula:




wherein

Y represents a bond, C₁₋₆ alkylene, -CO-, -CO-alkb- or -CO-alkd-O- (alkb and alkd are the same or different and each represents a C₁₋₆ alkylene or a bond);

R⁴ and R⁵ are the same or different, and each represents a hydrogen atom or C₁₋₆ alkyl, or R⁴ and R⁵, together with the adjacent carbon atom, form a ring optionally having substituents;

R⁶ represents an indolyl group optionally having substituents; and

Z represents piperidinyl optionally having substituents or piperazinyl optionally having substituents or a salt thereof, with a compound of the formula:



wherein

ring A represents a benzene ring, which may have 1 to 3 substituents selected from

(1) halogen atom,


- (2) nitro,
- (3) cyano,
- (4) hydroxy,
- (5) C₁₋₆ alkyl optionally having 1 to 5 halogen atoms,
- (6) C₆₋₁₄ aryl, which may have 1 to 5 substituents selected from halogen atom, hydroxy, C₁₋₆ alkyl optionally having 1 to 5 halogen atoms, C₁₋₆ alkoxy optionally having 1 to 5 halogen atoms, and C₁₋₆ alkyl-carbonyl optionally having 1 to 5 halogen atoms,
- (7) C₁₋₆ alkoxy optionally having 1 to 5 halogen atoms,
- (8) C₁₋₆ alkylthio optionally having 1 to 5 halogen atoms,
- (9) amino,
- (10) mono- or di-C₁₋₆ alkylamino,
- (11) C₁₋₆ alkyl-carboxamide optionally having 1 to 5 halogen atoms,
- (12) carbamoyl,
- (13) mono- or di-C₁₋₆ alkyl-carbamoyl,
- (14) C₁₋₆ alkyl-carbonyl optionally having 1 to 5 halogen atoms,
- (15) C₁₋₆ alkyl-sulfonyl optionally having 1 to 5 halogen atoms,
- (16) 5- to 7-membered non-aromatic heterocyclic group,
- (17) C₁₋₆ alkoxy-C₁₋₆ alkoxy,
- (18) 5- or 6-membered heterocyclic carbonyl,
- (19) carboxy,
- (20) C₁₋₆ alkoxy-carbonyl,

- (21) 5- or 6- ~~5- to 7-~~ membered aromatic heterocyclic group, which may have 1 to 3 substituents selected from C₁₋₆ alkyl optionally having 1 to 5 halogen atoms,
- (22) C₁₋₆ alkylsulfinyl optionally having 1 to 5 halogen atoms, and
- (23) C₃₋₈ cycloalkyl-C₁₋₆ alkoxy;

B represents a C₁₋₆ alkylene optionally having substituents;

R¹ and R² are the same or different, and each represents a hydrogen atom or C₁₋₆ alkyl; and

R³ represents a hydrogen atom; or a salt thereof to give a compound of the formula:



wherein

each symbol is as defined above; or a salt thereof, and optionally reacting the compound or a salt thereof with a compound of the formula: L⁴-Ya-Za wherein L⁴ represents a leaving group; Ya represents a bond, C₁₋₆ alkylene, -CO-, -CO-alkb- or -CO-alkd-O- (alkb and alkd are the same or different and each represents a C₁₋₆ alkylene or a bond); and Za represents a hydrogen atom, a halogen atom or a cyclic group optionally having substituents; or a salt thereof.

28. (Canceled)